A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study
Latest Information Update: 28 Feb 2025
At a glance
- Drugs Immune globulin (Primary)
- Indications Dermatomyositis
- Focus Registrational; Therapeutic Use
- Acronyms RECLAIIM
- Sponsors CSL Behring
- 24 Feb 2025 Status changed from active, no longer recruiting to discontinued.
- 04 Jul 2024 Planned End Date changed from 30 Nov 2027 to 22 May 2028.
- 04 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 22 May 2028.